Literature DB >> 27671987

Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy.

Nicholas Burwick1, Sarah A Buckley2, Zhao Ming Dong3, Robert E Richard1.   

Abstract

Lymphomatoid granulomatosis (LG) is a rare Epstein-Barr virus-driven lymphoproliferative disorder that generally arises in immunosuppressed patients and which can be life-threatening. Here we describe the development of pulmonary LG in a patient on long-term azathioprine for immune-mediated neuropathy. Although azathioprine carries a boxed warning for malignancy, its association specifically with LG, an otherwise rare entity, is poorly recognised. Early recognition of drug-induced LG is critical, since discontinuation of the offending agent, and implementation of effective therapy can provide rapid clinical benefit in some patients. In this case, rituximab was used as an effective treatment for LG, which also provided an additional benefit of controlling the patient's underlying neuropathy. Further research is needed to identify vulnerable patients who are at high risk of developing drug-induced LG. 2016 BMJ Publishing Group Ltd.

Entities:  

Year:  2016        PMID: 27671987      PMCID: PMC5051443          DOI: 10.1136/bcr-2016-216930

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Lymphomatoid granulomatosis: a unique complication of Crohn disease and its treatment in pediatrics.

Authors:  Sylvie Destombe; Dorothée Bouron-DalSoglio; Anne L Rougemont; Jean C Fournet; Philippe Ovetchkine; Josette Champagne; Colette Deslandres
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-05       Impact factor: 2.839

2.  Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy.

Authors:  L Katherine Martin; Pierluigi Porcu; Robert A Baiocchi; Jack W Erter; Abhik Ray Chaudhury
Journal:  Clin Adv Hematol Oncol       Date:  2009-01

Review 3.  Lymphomatoid granulomatosis.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

4.  Lymphomatoid granulomatosis.

Authors:  A A Liebow; C R Carrington; P J Friedman
Journal:  Hum Pathol       Date:  1972-12       Impact factor: 3.466

Review 5.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Authors:  Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases.

Authors:  A L Katzenstein; C B Carrington; A A Liebow
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

8.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors:  Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease.

Authors:  William Connors; Cameron Griffiths; Jay Patel; Paul J Belletrutti
Journal:  BMC Gastroenterol       Date:  2014-07-14       Impact factor: 3.067

10.  Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis.

Authors:  Athar Barakat; Karan Grover; Rohit Peshin
Journal:  Springerplus       Date:  2014-12-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.